Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI
Phase 1 / Phase 2 · 1 site
Search the registry
2,585 studies found
Phase 1 / Phase 2 · 1 site
Phase 1 · 1 site
Phase 1 / Phase 2 · 15 sites
Potential match only. Final eligibility is determined by the study team.